Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f - pneumococcal infections; immunization - vacciner - aktiv immunisering til forebyggelse af invasiv sygdom, lungebetændelse og akut otitismedium forårsaget af streptococcus pneumoniae hos spædbørn, børn og unge fra 6 uger til 17 år. aktiv immunisering til forebyggelse af invasiv sygdom forårsaget af streptococcus pneumoniae i voksne ≥18 år og ældre. se afsnit 4. 4 og 5. 1 for information om beskyttelse mod specifikke pneumokokserotyper. brug af prevenar 13 bør fastsættes på grundlag af de officielle anbefalinger under hensyntagen til risikoen for invasiv sygdom i forskellige aldersgrupper, underliggende co-morbiditet samt variation af serotype epidemiologi i forskellige geografiske områder.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokokinfektioner - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. se afsnit 4. 4 og 5. 1 for information om beskyttelse mod specifikke pneumokokserotyper. the use of vaxneuvance should be in accordance with official recommendations.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pneumokokinfektioner - vacciner - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. se afsnit 4. 4 og 5. 1 for information om beskyttelse mod specifikke pneumokokserotyper. apexxnar should be used in accordance with official recommendations. .

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vacciner - aktiv immunisering mod sygdom forårsaget af streptococcus pneumoniae serotyper 4, 6b, 9v, 14, 18 c, 19f og 23f (herunder sepsis, meningitis, pneumoni, bakteriæmi og akut otitis media) hos spædbørn og børn fra to måneder op til fem år. brug af prevenar bør fastsættes på grundlag af de officielle anbefalinger, der tager højde for den effekt af invasiv sygdom i forskellige aldersgrupper, samt variation af serotype epidemiologi i forskellige geografiske områder.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sanofi pasteur europe - haemophilus influenza type b polysaccharid - pulver og solvens til injektionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aj vaccines a/s - corynebacterium diphtheria, toxoid - injektionsvæske, suspension, enkeltdosisbeholder - 2 ie/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

aj vaccines a/s - corynebacterium diphtheria, toxoid - injektionsvæske, suspension, enkeltdosisbeholder - 30 ie/dosis

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

merck sharp & dohme b.v. - hepatitis a virus, stamme cr 326f (inaktiveret) - injektionsvæske, suspension, fyldt injektionssprøjte - 50 e./ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - immunologiske stoffer til suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. en anden vigtig bidragyder til vildsvin, skatole, kan også reduceres som en indirekte virkning. aggressive og seksuelle (montering) adfærd reduceres også. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid - meningitis, meningokok - vacciner - nimenrix er indiceret til aktiv immunisering af personer fra 6 uger mod invasive meningokoksygdomme forårsaget af neisseria meningitidis gruppe a, c, w-135 og y.